Skip to content

Head to head

BPC-157 against Larazotide

The grey-market gut peptide and the one that actually went through phase 3. Larazotide reached a phase 3 in celiac disease that did not meet its primary endpoint and was terminated by the sponsor without a published result, which is more than BPC-157 has been asked to survive.

Column A

BPC-157

Body Protection Compound 157

A pentadecapeptide with a large animal literature on tendon, ligament, muscle and gut healing, and a small human record: two rectal-enema studies run in Croatia, three uncontrolled clinic reports, and a randomized Phase 2 injury trial now recruiting.

Column B

Larazotide

Larazotide Acetate (AT-1001)

An investigational gut-barrier peptide for celiac disease that reached Phase 3 but was terminated by the sponsor without a published result.

Side by side, on the facts we can check

AttributeBPC-157Larazotide
CategoryHealing & RecoveryHealing & Recovery
FDA statusNot FDA-approved. Removed from Category 2 (April 2026); PCAC voted 8 to 6, one abstention, to recommend for compounding (July 2026) against the FDA reviewers' recommendation; awaiting FDA actionInvestigational; Phase 3 did not meet primary endpoint
Half-lifeUnder 30 minutes in plasma in a two-person pilot; the animal literature describes effects lasting hours to days.Short (acts locally in the gut)
Molecular weight1,419.5 Da~732 Da
MechanismIn animal work BPC-157 promotes angiogenesis, interacts with the nitric oxide system, and raises growth hormone receptor expression and growth factor signaling in tendon fibroblasts. No receptor or molecular target has been identified, which FDA's 2026 evaluation gave as one reason it could not judge biological plausibility. Human mechanistic work is limited to the observation that the peptide was not detectable in plasma after rectal dosing, and to a two-person pilot consistent with a plasma half-life under 30 minutes, against effects that animal studies describe as lasting hours to days.Antagonizes zonulin signaling to strengthen intestinal tight junctions and limit passage of gluten fragments across the gut lining.
Human studies cited53
Legal status, USNot approved; research use onlyInvestigational, not approved
open the BPC-157 profileopen the Larazotide profile

Frequently asked questions

What is the difference between BPC-157 and Larazotide?

BPC-157: A pentadecapeptide with a large animal literature on tendon, ligament, muscle and gut healing, and a small human record: two rectal-enema studies run in Croatia, three uncontrolled clinic reports, and a randomized Phase 2 injury trial now recruiting. Larazotide: An investigational gut-barrier peptide for celiac disease that reached Phase 3 but was terminated by the sponsor without a published result.

Which has stronger research evidence, BPC-157 or Larazotide?

This database does not grade compounds. It counts what was run in people: 5 of the 12 studies cited on the BPC-157 profile were human work, against 3 of 3 for Larazotide. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.

Are BPC-157 and Larazotide FDA-approved?

BPC-157: Not FDA-approved. Removed from Category 2 (April 2026); PCAC voted 8 to 6, one abstention, to recommend for compounding (July 2026) against the FDA reviewers' recommendation; awaiting FDA action. Larazotide: Investigational; Phase 3 did not meet primary endpoint.

Related posts

Blog articles that cover BPC-157 or Larazotide, newest first.

Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.